Aminochalcone 4AAF is a neuroprotective agent that exerts anxiolytic effects through GABAA and 5-HT receptors. Aminochalcone 4AAF has high selectivity for 5-HT3A and 5-HT2C receptors, and stimulates allosteric behavior toward the 5-HT2A receptor. Aminochalcone 4AAF shows hypoglycemic effects and reduces the level of ROS in the liver. Aminochalcone 4AAF delays the clonic stage of the epileptic seizures . Aminochalcone 4AAF can be used in the study of anxiety, hyperglycemia, and seizures.

ON 01500 is a tubulin inhibitor with a Kd of 21 nM. ON 01500 exerts microtubule-destabilizing effects in cells. ON 01500 can be used the study of cancers.

BMS-025 is a orthosteric STING agonist. BMS-025 can induces chemical shift of STING M271 residue, further activating STING IFN signaling. BMS-025 can be used for monogenic autoinflammatory disease like SAVI disease research.

cis-NVP-ADW742 (cis-ADW742) is a cis isomer of NVP-ADW742. NVP-ADW742 is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC50 of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC50 of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells.

DMU759 is a Lysyl-tRNA synthetase 1 (KRS1) inhibitor. DMU759 has potent anti-kinetoplastid activity against Trypanosoma cruzi , Trypanosoma brucei and Leishmania donovani. DMU759 significantly reduces parasitemia in acute Chagas disease mice model. DMU759 can be used for parasitic infection like Chagas disease research.

DMU371 is a Trypanosoma cruzi lysyl-tRNA synthetase 1 (KRS1) inhibitor (IC50=185 nM). DMU371 is promising for research of infectious diseases.

Aβ1–42 aggregation inhibitor 3 (Compound 3b) is an acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor (IC50 values are 1.634 and 0.0285 μM, respectively). Aβ1–42 aggregation inhibitor 3 can inhibit the aggregation of Aβ1-42. Aβ1–42 aggregation inhibitor can be used in Alzheimer's disease (AD) research.

AR-C66096 is a potent and selective antagonist of the Gi-coupled P2Y12 receptor. AR-C66096 suppresses platelet thrombus stability under physiological flow conditions. AR-C66096 inhibits ADP-induced aggregation in whole blood aggregometry. AR-C66096 can be used for antithrombotic research.

RNase L ligand 3 is a RNase L ligand. RNase L ligand 3 can be used for synthesis of F3-PEG8-RiboTAC.

PBRM1/SMARCA2,4-ligand-1 (Compound 4) is a Ligand for Target Protein for PROTAC that binds to PBRM1, SMARCA2, and SMARCA4. PBRM1/SMARCA2,4-ligand-1 is a potent SMARCA4 bromodomain inhibitor. PBRM1/SMARCA2,4-ligand-1 can be used to synthesize PROTAC AU-24118.

SLC-391 is a selective, orally active AXL inhibitor with an IC50 of 9.6 nM. SLC-391 has antiviral activity.

SM 10888 is a selective and orally active cholinesterase (ChE) inhibitor. SM 10888 can increase brain acetylcholine release. SM 10888 can be used for the research of neurological disease, such as Alzheimer's disease.

ETI60 is an orally active, selective TLR inhibitor that targets the nucleoside-binding Site I on TLR7 (IC50 = 0.68 μM) and TLR9 (IC50 = 0.12 μM), sparing surface TLRs (including TLR1/TLR2, TLR2/TLR6, TLR4 and TLR5). ETI60 potently inhibits endosomal TLR-mediated pro-inflammatory signaling with nanomolar activity in cellular, biophysical and in vivo assays. ETI60 modulates the expression of genes associated with inflammation. ETI60 effectively ameliorates symptoms in mouse models of psoriasis, and systemic lupus erythematosus (SLE). ETI60 can be used for autoimmune and inflammatory diseases research.

(R)-SW033291 is the R-type enantiomer of SW033291. (R)-SW033291 is a potent and high-affinity inhibitor of 15-PGDH. (R)-SW033291 increases prostaglandin PGE2 levels in bone marrow and other tissues. (R)-SW033291 also promotes tissue regeneration.

AP232 is a selective U2AF1-UHM Inhibitor with an IC50 of 7.96 μM. AP232 exhibits 2.8-24-fold selectivity against other UHM-containing proteins. AP232 exerts anti-leukemia activity and shows higher activities in cell lines carrying splicing factor mutations. AP232 can induce leukemia cells G2/M and G1 arrest, impair lysosome acidification, and inhibit autophagy. AP232 can be used for the research of cancer, such as Leukemia.

Negamycin (hydrochloride) is a dipeptide antibiotic. Negamycin (hydrochloride) can restore dystrophin expression in skeletal and cardiac muscles in mdx Duchenne muscular dystrophy (DMD) murine model. Negamycin (hydrochloride) can bind to a partial sequence of the eukaryotic rRNA-decoding A-site. Negamycin (hydrochloride) can be studied in DMD research.

Ro 31-8220 formic is a potent PKC inhibitor, with IC50s of 5, 24, 14, 27, 24 and 23 nM for PKCα, PKCβI, PKCβII, PKCγ, PKCε and rat brain PKC, respectively. Ro 31-8220 formic also significantly inhibits MAPKAP-K1b, MSK1, S6K1 and GSK3β (IC50s, 3, 8, 15, and 38 nM, respectively). Ro 31-8220 formic can also inhibit the expression of MKP-1, induce the expression of c-Jun, and activate JNK, and these effects possess pharmacological properties independent of PKC.

JBPOS-0101 is a phenyl carbamate compound. JBPOS-0101 exhibits neuroprotective and antiepileptic effects. JBPOS-0101 can attenuate the accumulation of Aβ in 5XFAD mouse brains and rescue the deficits in learning and memory. JBPOS-0101 can be used for the research of neurological disease, such as Alzheimer's disease (AD).

TXA497 is a potent local topical bactericide. TXA497 exerts its bactericidal effect by interfering with the polymerization kinetics of the bacterial cell division protein FtsZ, rather than inhibiting it. TXA497 shows strong activity against various Staphylococcus aureus strains, including MRSA and MSSA, with an MIC value ranging from 1.0 to 2.0 μg/mL. TXA497 skin deposition is concentration-dependent in its formulation, consistent with Fick's first law. TXA497 has limited systemic permeability through the lipid pathway of the stratum corneum and is easily absorbed through this route. TXA497 can be used for research on topical bactericidal agents.

FR-β ligand 1 (III), a folate receptor-targeting ligand, possesses antitumor activity, high selectivity, and stronger affinity for folate receptor.

Bis-Cl-ANT-ATP (tetrasodium) is a fluorescent ATP derivative, which undergo spontaneous isomerization. Bis-Cl-ANT-ATP (tetrasodium) selectively inhibits B. pertussis Adenylyl Cyclase (AC) toxin CyaA over mammalian AC1, AC2, and AC5 (Kis = 16, 1,700, 2,400, and 1,600 nM, respectively). Bis-Br-ANT-ATP (tetrasodium) can be used in the study of whooping cough.

Bis-Br-ANT-ATP (tetrasodium) is a fluorescent derivative of adenosine-5’-triphosphate (ATP). Bis-Br-ANT-ATP (tetrasodium) selectively inhibits B. pertussis adenylyl cyclase toxin CyaA (Ki: 12.6 nM). Bis-Br-ANT-ATP (tetrasodium) can be used in Whooping cough research.

KARI 201 hydrochloride is a selective, brain penetrant pand competitive acid sphingomyelinase (ASM) inhibitor with an IC50 of 338.3?nM. KARI 201 hydrochloride is a ghrelin receptor agonist. KARI 201 hydrochloride improves neuropathological features of Alzheimer's disease.

Basivarsen linker is a linker used in Zeleciment basivarsen for coupling a TfR1-binding Fab Zeleciment) and an antisense oligonucleotide. Zeleciment basivarsen is an antibody-oligonucleotide conjugate (AOC) designed to target mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA for RHase H-mediated degradation to correct splicing. It is used for the study of myotonic dystrophy type 1 (DM1).

LY-228729 is a selective 5-HT1A receptor agonist. LY-228729 can reduce the rearing frequency of rats and decrease their activity in the central area in the open field test. LY-228729 can reduce the immobility time of rats and increase their swimming time in the forced swim test. LY-228729 can be used in the research of neurological diseases.

Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC50s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect.

U93385 is a 5-HT₁A receptor agonist. U93385 exhibits no significant α₂ adrenergic, D₂ dopamine, or other receptor activities. U93385 has a heart rate regulating effect, stimulating the vagus nerve to induce bradycardia. U93385 can be used to study the 5-HT₁A receptor-mediated vagal nerve tolerance mechanism.

TQ-3959 is an orally active BTK PROTAC degrader, with a DC50 of 14.6 nM. TQ-3959 exerts antiproliferative activity against both wild-type BTK and C481S mutant BTK cell lines. TQ-3959 exhibits tumor growth inhibition in female NOD-SCID mice bearing TMD-8 xenografts. TQ-3959 can be used in the research on B-cell malignancies such as lymphoma.

BTK ligand 16 is a BTK ligand that can be used for synthesis of TQ-3959.

(R,R)-Bexobrutideg is the (R,R)-enantiomer of Bexobrutideg. Bexobrutideg is an orally active PROTAC that induces specific BTK protein degradation via a cereblon E3 ligase (CRBN) complex without degrading other cereblon neo substrates. Bexobrutideg mediates potent anti-inflammatory activity through BTK degradation, thereby inhibiting B cell activation. Bexobrutideg exhibits potent tumor growth inhibition in TMD8 xenograft models containing wild-type BTK or BTKi resistance mutations. Bexobrutideg is effective in a mouse model of collagen-induced arthritis (CIA). Bexobrutideg can cross the blood-brain barrier. NX-5948 consists of a target protein ligand, a linker, and a VHL E3 ubiquitin ligase.